June 25, 2021
Symtomax Portugal, a medical cannabis company, has announced approval to start growing from INFARMED, the Portuguese regulator for the pharmaceutical industry in Portugal. The approval enables Symtomax to grow, import and export dried flowers in GACP quality, which are produced in their plant in Portugal.
Symtomax was founded in 2017 with the aim of promoting alternative and effective products to improve people’s health and well-being. The Symtomax team of experts has decades of experience growing cannabis and adheres to strict procedural and environmental protocols to maximize purity, quality and consistency.
The company has built partnerships that improve consumer access to the best products worldwide and invested in industry-leading research and development. This strategy enables Symtomax to use leading technology to develop high quality and technologically advanced cannabis products that can be sold around the world.
Symtomax site of 105 hectares, 95 hectares of which are approved for the cultivation of medicinal flowers. The company has a wide variety of sativa-dominant, indica-dominant, hybrid, and CBD strains. The license will allow Symtomax to grow into a vertically integrated cannabis company that will grow both indoor and outdoor facilities with future plans for research and development, including processing, packaging and distribution of medicinal cannabis oil and other cannabinoid-based products .
The company has forged strategic partnerships with leading industrial companies dedicated to the promotion and development of cannabis for medicinal purposes to treat a range of different conditions including cancer, arthritis, Alzheimer’s, depression, dementia, anxiety, and even its use to treat eating disorders such as Anorexia.
This INFARMED approval is a major milestone for the company and firmly positions Symtomax as the leading supplier of cannabis flowers to the medical industry across Europe and beyond.
Further information is available at: www.symtomax.com